3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectal ultrasound-guided biopsy

JIE CHEN1*, XIAO-LEI YI1*, LI-XIN JIANG1, REN WANG1, JUN-GONG ZHAO2, YUE-HUA LI2 and BING HU1

1Department of Ultrasound in Medicine, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai Institute of Ultrasound in Medicine; 2Department of Radiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China

Received April 8, 2014; Accepted October 21, 2014

DOI: 10.3892/etm.2014.2061

Abstract. The detection rate of prostate cancer (PCa) using traditional biopsy guided by transrectal ultrasound (TRUS) is not satisfactory. The aim of this study was to determine the utility of 3-Tesla (3-T) magnetic resonance imaging (MRI) prior to TRUS-guided prostate biopsy and to investigate which subgroup of patients had the most evident improvement in PCa detection rate. A total of 420 patients underwent 3-T MRI examination prior to the first prostate biopsy and the positions of suspicious areas were recorded respectively. TRUS-guided biopsy regimes included systematic 12-core biopsy and targeted biopsy identified by MRI. Patients were divided into subgroups according to their serum prostate-specific antigen (PSA) levels, PSA density (PSAD), prostate volume, TRUS findings and digital rectal examination (DRE) findings. The ability of MRI to improve the cancer detection rate was evaluated. The biopsy positive rate of PCa was 41.2% (173/420), and 41 of the 173 (23.7%) patients were detected only by targeted biopsy in the MRI-suspicious area. Compared with the systematic biopsy, the positive rate was significantly improved by the additional targeted biopsy (P=0.0033). The highest improvement of detection rate was observed in patients with a PSA level of 4-10 ng/ml, PSA density of 0.12-0.20 ng/ml2, prostate volume >50 ml, negative TRUS findings and negative DRE findings (P<0.05). Therefore, it is considered that 3-T MRI examination could improve the PCa detection rate on first biopsy, particularly in patients with a PSA level of 4-10 ng/ml, PSA density of 0.12-0.20 ng/ml2, prostate volume of >50 ml, negative TRUS findings and negative DRE findings.

Introduction

Transrectal ultrasound (TRUS)-guided biopsy is the most widely used method for the histological diagnosis of prostate cancer (PCa), which provides real-time imaging of the prostate at a relatively low cost. However, clinical practice suggests that systematic biopsy may be associated with a high false-negative rate (1), and systematic repeat biopsy does not give a satisfactory cancer detection rate (2), in addition to increasing the risk of complications and discomfort to the patient. Additional targeted biopsy in suspicious areas identified by TRUS may improve detection rates, as the sensitivity of conventional TRUS for cancer lesions is relatively low (3,4). Even new imaging techniques such as sonoelastography and contrast-enhanced TRUS do not provide a considerable benefit to the diagnosis of PCa (5,6).

It has been reported that T2-weighted (T2W) magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) are useful for diagnosing PCa (7,8). Therefore, there has been an increasing interest in the use of MRI for the diagnosis of PCa. MRI has been used to guide prostatic biopsy successfully, as first reported in 2000; however, MRI guidance is time-consuming and requires specific biopsy equipment (9). It has been hypothesized that TRUS-guided targeted biopsy in suspicious areas identified by MRI has the potential to obtain a high positive rate; however, few patients have been enrolled in studies to investigate this (10,11). The study by Singh et al revealed that patient selection, specifically whether they had undergone a negative TRUS-guided biopsy or not and the different interval between two biopsies, influenced the PCa detection rate (12). To study whether MRI is able to increase the PCa detection rate generally, prospective research is required to compare the detection rate between patients undergoing conventional TRUS and those additionally examined by MRI.

The present study was conducted to investigate whether 3-Tesla (3-T) multiparametric MRI prior to biopsy improved the PCa detection rate in patients at their first TRUS-guided biopsies, and to investigate which subgroup had the most evident improvement in PCa detection rate.

Materials and methods

Subjects. Between June 2008 and December 2013, 429 consecutive patients (median age, 67 years; range, 45-91
years) underwent 3-T multiparametric MRI prior to their first TRUS-guided prostate biopsies. All patients presented as a result of abnormal digital rectal examination (DRE) findings and/or persistently elevated serum prostate-specific antigen (PSA) levels. Nine cases were excluded due to DWI artifacts resulting from movement of the patient during image acquisition. In the remaining 420 patients, the median PSA level was 9.73 (2.43-35.65) ng/ml and the median prostate volume was 44.82 (21.22-83.22) ml. There were 52 patients with abnormal DRE findings. MRI was performed 2-14 (median 7) days prior to biopsy. The study was approved by the Ethics Committee of Medical College, Shanghai Jiaotong University (Shanghai, China). Signed informed consent was obtained from all patients.

**MRI examination.** MRI was performed with a 3-T MRI system (Achieva; Philips, Best, The Netherlands), using a pelvic phased-array coil. First, conventional MRI was performed, including T1-weighted (T1W), T2W and T2W spectral presaturation attenuated inversion recovery (SPAIR). The repetition time/echo time (TR/TE) in T1W, T2W and T2W SPAIR imaging were 353 msec/10 msec, 2,754 msec/80 msec and 2,879 msec/80 msec, respectively. The other main parameters were as follows: thickness, 3 mm; spacing, 1 mm, field of view (FOV), 160x200 mm; matrix, 128x132; number of signal averages (NSA), 3 times. Then, a DWI sequence was performed. The main parameters were as follows: b value, 0 and 1,000 sec/mm²; TR/TE 2,500 msec/60 msec; FOV,160x144 mm; matrix, 80x60; thickness, 6 mm; NSA 4 times. An apparent diffusion coefficient (ADC) map was obtained by the computer automatically.

**Biopsy protocol.** Transperineal prostate biopsy was performed by two operators, guided by transrectal ultrasound. Using a 16-gauge core biopsy gun (Bard Magnum™; Bard Biopsy Systems, Tempe, AZ, USA), a 12-core systematic biopsy (10 cores distributed in a fan-shape from the peripheral zone and 2 cores from the transition zone) was first performed without knowledge of the location of suspicious MRI findings. After two operators had reviewed the information concerning the MRI-suspicious area recorded by the radiologist, targeted biopsy was performed. One or two cores were taken from each suspicious area. Whether the needle was in the correct site was determined by measuring the distance of the needle to the exterior margin and posterior border of prostate, which coincided with the same distances on the corresponding axial MRI.

**Statistical analysis.** Differences were analyzed using the Student's t-test, Kruskal-Wallis test and Chi-square test. P<0.05 was considered to indicate a significant difference. All statistical analyses were performed using SAS software, version 9.13 (SAS Institute, Inc., Cary, NC, USA).

**Results**

Clinical characteristics of the 420 patients are presented in Table I. PCa was detected in 173 patients (41.2%, 173/420). Among these 173 patients, 41 patients (23.7%, 41/173) were detected by targeted biopsy, but not by systematic biopsy (Fig. 1); 28 patients (16.2%, 28/173) were detected by systematic biopsy, but not by targeted biopsy, and 104 patients (60.1%, 104/173) were detected by both systematic biopsy and targeted biopsy. The increase in the cancer detection rate by targeted biopsy identified by MRI was 9.8% (41/420; P=0.0033). As shown in Table II, among the three groups with PCa detected by different biopsy regimens there were significant differences in serum PSA level, PSAD, prostate volume, DRE findings and TRUS findings, but no differences in age and the biopsy Gleason score.
The efficiency of additional targeted biopsy identified by MRI on the cancer detection rate in different subgroups of patients according to PSA level, PSAD, prostate volume, TRUS findings, and DRE findings is summarized in Table III. The improvement of the cancer detection rate was 9.8% in all cases. There was significant increase in the cancer detection rate in the patient subgroup with a PSA level of 4-10 ng/ml, PSAD of 0.12-0.20 ng/ml^2, prostate volume >50 ml, negative TRUS findings and negative DRE findings, and the P-values were 0.0256, 0.0133, 0.0099, 0.0027 and 0.0037, respectively.

### Discussion

Since PCa is often multifocal and the volume of prostate sampled by biopsy is relatively small, there is high false-negative rate in conventional TRUS-guided systematic biopsy.
Various regimens have been devised to improve the diagnostic yield of prostate biopsies, such as increasing the number of biopsy cores and sampling from the suspicious areas of TRUS, for example (15,16). However, the ideal strategy for prostate biopsy has not yet been identified. A study revealed that even saturation biopsy did not significantly improve cancer detection compared with standard biopsy, and was not able to rule out the presence of PCa (17).

MRI has been increasingly used to detect and locate lesions of PCa. 3-T MRI is considered to be superior to 1.5-T MRI with a higher signal to noise ratio and greater spatial resolution (18). Currently, the optimal MRI techniques for PCa are the integrated use of multimodal MRIs, for example, DWI and T2W. DWI has certain advantages, such as fast imaging, without the need for injection of contrast agents. Cancer lesions often show high signal intensity compared with benign tissues, regardless of whether they are in the peripheral zone or in the transition zone.

Previous studies have found that TRUS-guided repeat biopsies alone result in positive rates of 10-41.1% (1,19-21). When MRI data are added, positive rates for TRUS-guided repeat biopsies of between 24.7 and 40.5% have been observed (10,22,23). It has been suggested that the cancer detection rate might be influenced by previous biopsy techniques and the interval between biopsies (24,25). However, it remains unclear whether additional MRI examination prior to biopsy is useful. Lattouf et al observed that MRI prior to TRUS-guided repeat biopsy tended to give higher cancer yields, but the difference was not statistically significant (26). Furthermore, to the best of our knowledge, there are no studies evaluating the advantage of MRI in a large series of cases prior to first biopsy in addition to the standard 12-core systematic biopsy.

In the present study, the overall cancer detection rate was 41.2%, and 41 out of the 173 prostate cancer patients were detected only by targeted biopsy identified by MRI. The improvement of cancer detection rate by targeted biopsy was 9.8% (41/420; P=0.0033). Targeted biopsy identified by MRI may be useful to improve the positive rate on first biopsy. This finding differs from the results of Shigemura et al who reported that only 1.04% of cancers had positive cores in MRI targeted biopsy alone (27). This difference may be caused by differences in prostate volume (mean 44.82 vs. 31.9 ml) and serum PSA level (mean 9.73 vs. 8.58 ng/ml) between the two studies. Previous studies have identified patient subgroups with high positive rates in repeat biopsy; there are high false negative rates in patients with a large prostate volume and elevated serum PSA levels (20,28).

In the subgroup analysis of the present study, the improvement of the cancer detection rate by targeted biopsy was 10.1%, 12.4%, 14.0%, 10.9% and 10.1%, respectively, in patients with a PSA level of 4-10 ng/ml, PSAD of 0.12-0.20 ng/ml, prostate

| Characteristics                  | No. of patients | No. of cancer patients | Increase in the no. of cancer patients | Increase in the positive rate (%) |
|----------------------------------|----------------|------------------------|----------------------------------------|----------------------------------|
| PSA (ng/ml)                      |                |                        |                                        |                                  |
| <4                               | 56             | 12                     | 3                                      | 3/56 (5.4)                       |
| 4-10                             | 218            | 84                     | 22                                     | 22/218 (10.1)                    |
| ≥10                              | 146            | 77                     | 16                                     | 16/146 (11.0)                    |
| Prostate volume (ml)             |                |                        |                                        |                                  |
| <30                              | 105            | 52                     | 5                                      | 5/105 (4.8)                      |
| 30-50                            | 172            | 68                     | 16                                     | 16/172 (9.3)                     |
| ≥50                              | 143            | 53                     | 20                                     | 20/143 (14.0)                     |
| PSAD (ng/ml²)                    |                |                        |                                        |                                  |
| <0.12                            | 80             | 16                     | 5                                      | 5/80 (6.3)                       |
| 0.12-0.20                        | 185            | 80                     | 23                                     | 23/185 (12.4)                    |
| ≥0.20                            | 155            | 77                     | 13                                     | 13/155 (8.4)                     |
| TRUS                             |                |                        |                                        |                                  |
| Normal                           | 302            | 100                    | 33                                     | 33/302 (10.9)                    |
| Abnormal                         | 118            | 73                     | 8                                      | 8/118 (6.8)                      |
| DRE                              |                |                        |                                        |                                  |
| Normal                           | 368            | 139                    | 37                                     | 37/368 (10.1)                    |
| Abnormal                         | 52             | 34                     | 4                                      | 4/52 (7.7)                       |
| Overall                          | 420            | 173                    | 41                                     | 41/420 (9.8)                     |

These values were calculated by Chi-square test. MRI, magnetic resonance imaging; PSA, prostate-specific antigen; PSA density; DRE, digital rectal examination; TRUS, transrectal ultrasound. *The positive rate was significantly improved, with P-values of 0.0256, 0.0099, 0.0133, 0.0027, 0.0037 and 0.0033, respectively.
volume of >50 ml, negative TRUS findings and negative DRE findings, with P-values of 0.0256, 0.0133, 0.0099, 0.0027 and 0.0037, respectively. A significant increase in the PCA detection rate by targeted biopsy was found in the subgroup with a PSA level of 4-10 ng/ml while there was no significant difference in the subgroups with a PSA level of <4 ng/ml or >10 ng/ml. This may be explained by the fact that, as a sensitive marker for PCa, a PSA level of <4 ng/ml presents a low incidence of PCa. Despite the addition of MRI data, there is only a small chance of detecting more cancer. By contrast, when the PSA level is >10 ng/ml, the cancer lesions are often so evident that they are detected by systematic biopsy. In patients with a PSA level of 4-10 ng/ml, a considerable number of lesions may remain undetected by systematic biopsy (29), which provides an opportunity for MRI to identify suspicious areas due to its high sensitivity. For similar reasons, the subgroup with a PSAD of 0.12-0.20 ng/ml\textsuperscript{2} obtained the most marked increase in PCA detection rate compared with the other two subgroups. It has previously been reported that a significantly increased prostate volume is one of the important factors responsible for PCa being missed by biopsy (30,31). Since PCa is a multifocal disease, the biopsy technique only provides a limited sample volume of the prostate. The results of the present study showed that the subgroup with a prostate volume of >50 ml obtained the greatest increase in the PCa detection rate. This was in accord with previous studies (30-32). Due to the higher sensitivity of MRI for prostate cancer, it is possible for the detection rate to be improved more significantly in the subgroup of patients with negative TRUS findings or negative DRE findings. For patients with abnormal TRUS or DRE findings, the traditional TRUS-guided biopsy was able to diagnose PCa, and additional targeted biopsies in MRI-suspicious areas were not able to increase the detection rate significantly.

One limitation of the present study was that the accuracy of targeted biopsies may have been reduced since they were not performed with real-time guided-MRI, which could not be used routinely due to it being time-consuming and requiring specific biopsy equipment. A promising imaging technique comprising a fusion of MRI and TRUS may have the ability to improve the accuracy of prostate biopsy (33). Investigation of the value of this technique in our further studies is planned. Another limitation of the present study was that the MRI results were not compared with specimens of radical prostatectomy. Too small a specimen may cause the pathologist to draw a false negative diagnosis. Additionally, the judgment of normal or suspicious MRI imaging was partly operator-dependent. The confidence levels for the probability of malignancy were used to minimize the subjectivity.

In conclusion, this study indicates that MRI may be recommended particularly for the subgroup of patients with a PSA level of 4-10 ng/ml, PSAD of 0.12-0.20 ng/ml\textsuperscript{2}, prostate volume of >50 ml, negative TRUS findings and negative DRE findings. 3-T multiparametric MRI has the potential to improve the prostate cancer detection rate on first biopsy.

Acknowledgements

This study was supported by grants from the National Nature Science Foundation (30770562 and 81371574).

References

1. Mitterberger MJ, Aigner F, Horninger W, et al: Comparative efficiency of contrast-enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection. Eur Radiol 20: 2791-2796, 2010.
2. Ploussard G, Nicolaie N, Marchand C, et al: Risk of repeat biopsy and prostate cancer detection after an initial extended needle negative biopsy: longitudinal follow-up from a prospective trial. BJU Int 111: 988-996, 2013.
3. Nelson ED, Slotoroff CB, Gomella LG and Halpern EP: Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. Urology 70: 1136-1140, 2007.
4. Chen MK, Luo Y, Zhang H, et al: Investigation of optimal prostate biopsy schemes for Chinese patients with different clinical characteristics. Urol Int 89: 425-432, 2012.
5. Kamoi K, Okihara K, Ochiai A, et al: The utility of transrectal real-time elastography in the diagnosis of prostate cancer. Ultrasound Med Biol 34: 1025-1032, 2008.
6. Puech P, Huglo D, Petyt G, Lemaître L and Villers A: Imaging of organ-confined prostate cancer: functional ultrasound. MRI and PET/computed tomography. Curr Opin Urol 19: 168-176, 2009.
7. Miao H, Fukatsu H and Ishigaki T: Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 61: 297-302, 2007.
8. Osugi K, Tanimoto A, Nakashima J, et al: What is the most effective tool for detecting prostate cancer using a standard MR scanner? Magn Reson Med Sci 12: 271-280, 2013.
9. D'Amico AV, Tampeny CM, Cormack R, et al: Transperineal magnetic resonance image guided prostate biopsy. J Urol 164: 385-387, 2000.
10. Park BK, Lee HM, Kim CK, Choi HY and Park JW: Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before biopsy. Invest Radiol 43: 789-793, 2008.
11. Hambrock T, Somford DM, Hoeks C, et al: Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 183: 520-527, 2010.
12. Singh AK, Krieger A, Lattouf JB, et al: Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. BJU Int 101: 181-185, 2008.
13. Wang R, Chen JJ, Zhou YC, et al: Evaluation of diffusion-weighted magnetic resonance imaging and contrast-enhanced harmonic ultrasonography in detection and location of prostate transition-zone cancer. J Int Med Res 39: 256-266, 2011.
14. Eri LM, Thomsassen H, Bennhovd B and Håheim LL: Accuracy and repeatability of prostate volume measurement by transrectal ultrasound. Prostate Cancer Prostatic Dis 5: 273-278, 2002.
15. Abdollah F, Scattoni V, Baber M, et al: The role of transrectal saturation biopsy in tumour localisation: pathological correlation after retroperitoneal radical prostatectomy and implication for focal ablative therapy. BJU Int 108: 366-371, 2011.
16. Salomon G, Drews N, Autier P, et al: Incremental detection rate of prostate cancer by real-time elastography targeted biopsies in combination with a conventional 10-core biopsy in 1,024 consecutive patients. BJU Int 113: 548-553, 2014.
17. Jones JS, Patel A, Schoenfield L, et al: Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol 175: 485-488, 2006.
18. Rouvière O, Hartman RP and Lyonnet D: Prostate MR imaging at high-field strength: evolution or revolution? Eur Radiol 16: 276-284, 2006.
19. Busby JE and Evans CP: Determining variables for repeat prostate biopsy. Prostate Cancer Prostatic Dis 7: 93-98, 2004.
20. Park SJ, Miyake H, Haru I and Eto H: Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. Int J Urol 10: 68-71, 2003.
21. Chun FK, de la Taille A, van Poppel H, et al: Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 56: 659-667, 2009.
22. Cheikh AB, Girouin N, Colombel M, et al: Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 19: 770-778, 2009.
23. Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr and Figueiredo E: Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 236: 903-910, 2005.

24. Eskicorapci SY, Guliye F, Islamoglu E, Ergen A and Ozen H: The effect of prior biopsy scheme on prostate cancer detection for repeat biopsy population; results of the 14-core prostate biopsy technique. Int Urol Nephrol 39: 189-195, 2007.

25. Scattoni V, Maccagnano C, Zanni G, et al: Is extended and saturation biopsy necessary? Int J Urol 17: 432-447, 2010.

26. Lattouf JB, Grubb RL 3rd, Lee SJ, et al: Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int 99: 1041-1046, 2007.

27. Shigemura K, Motoyama S and Yamashita M: Do additional cores from MRI cancer-suspicious lesions to systematic 12-core transrectal prostate biopsy give better cancer detection? Urol Int 88: 145-149, 2012.

28. Ceylan C, Doluoglu OG, Aglamis E and Baytok O: Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in the determination of prostate cancer and the importance of prostate volume. Can Urol Assoc J 8: E81-E85, 2014.

29. Djavan B, Zlotta A, Remzi M, et al: Optimal predictors of prostate cancer on report prostate biopsy: a prospective study of 1,051 men. L Urol 163: 1144-1148, 2000.

30. Ankerst DP, Till C, Boeck A, et al: Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. Urology 82: 1076-1081, 2013.

31. Elshafei A, Li YH, Hatem A, et al: The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy. Prostate 73: 1796-1802, 2013.

32. Kuligowaka E, Barish MA, Fenlon HM and Blake M: Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers. Radiology 220: 757-764, 2001.

33. Ukimura O, Hirahara N, Fujihara A, et al: Technique for a hybrid system of real-time transrectal ultrasound with preoperative magnetic resonance imaging in the guidance of targeted prostate biopsy. Int J Urol 17: 890-893, 2010.